ClinicalTrials.gg
RecruitingNCT05417568Updated May 15, 2026

Oxalate-Driven Host Responses in Kidney Stone Disease

An interventional study of Low Oxalate Diet and High Oxalate Diet in Kidney Stones, sponsored by University of Alabama at Birmingham. Recruiting at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-15.

Sponsored by University of Alabama at Birmingham · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Kidney Calculi by University of Alabama at Birmingham — 6 open to participants now, 12 under way, none of them phase 3. Kidney Calculi · University of Alabama at Birmingham.

Planned enrollment
2nd of 17
88 · median 40
Started
2023
the only one that year
No phase
17 of 17
6 open now
Primary completion
2027-05
later than 4 of 11 live
Registered
13th of 17
by date

Among the 17 studies in Kidney Calculi by University of Alabama at Birmingham, this one is the 2nd largest by planned enrollment, is the only one that started in 2023, is one of 17 with no phase, reaches primary completion later than 4 of the 11 other live ones, and was the 13th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

6 of the 17 studies in Kidney Calculi by University of Alabama at Birmingham are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Kidney Calculi by University of Alabama at Birmingham, or all of them as a file.
02

Study summary

This study is looking to understand the role of oxalate on kidney stone development and immunity. This study will enroll healthy participants and participants with calcium oxalate kidney stones (CaOx KS). Participants will be in this study for about 3 weeks, consume controlled diets, and provide blood and urine specimens.

Read the detailed description

The purpose of this longitudinal study is to examine the effects of dietary oxalate on nanocrystalluria and the immune system. Oxalate is a small molecule found in plants and plant-derived food. It has been shown that meals containing high amounts of oxalate can increase urinary oxalate excretion, which is a risk factor for calcium oxalate kidney stones (CaOx KS). Small increases in oxalate can stimulate urinary crystals to form which can elicit an immune response. This study consists of having healthy subjects and patients with CaOx KS consume both low and oxalate enriched diets to evaluate the effect of oxalate on urinary crystals and immune responses. Participants will receive a low or high oxalate diet for 4 days prior to having a wash-out period for 6 days. Participants will then crossover to the opposite oxalate diet for four more days.

03

Conditions studied

  • Kidney Stones

Browse trials for

Keywords

  • Kidney stones
  • Dietary oxalate
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women between the ages of 18 and 60 years old.
  • Able to provide .
  • between 20-30 kg/m2.
  • Non-tobacco users or not pregnant/breastfeeding/nursing.
  • Normal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Must accurately collect two 24-hour urine collections within 20% of the appropriate ratio of creatinine (mg)/body weight (kg) for respective gender.
  • Healthy subjects: No history of CaOx KS or other medical conditions.
  • Patients with CaOx KS: Recent stone composition > 50% CaOx; no uric acid, struvite, or carbonate apatite stone content. Must be first-time or recurrent CaOx stone former (last stone event ≤ 3 years).
  • Willing to not consume supplements (i.e. vitamins, Ca (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, and probiotics) for 2 weeks before the study and during the study.
  • Willing to abstain from vigorous exercise during the study as this may compromise immune function.
  • Willing to consume diets provided only by the UAB CCTS Bionutrition Core. No food allergies or intolerance to any of the foods on the study menus.
  • Willing to accurately collect 24-hour urine samples, and to have blood drawn throughout the study.
  • If on medications for KS prevention (e.g. thiazides, citrate supplementation excluding calcium citrate), patients must be on a stable dose regimen for at least 8 weeks prior to and during screening, with no changes in dosing anticipated during the study. Patients should not take allopurinol for 2 weeks prior to screening since allopurinol has antioxidant properties.

Exclusion criteria

Exclusion Criteria:

  • Failure to meet the inclusion criteria or physician refusal.
  • Inability to sign and read the .
  • Any medical, psychiatric, or social conditions that would prohibit participants from abiding by the study requirements.
  • ˃30 kg/m2 and \<20 kg/m2
  • Tobacco users or pregnant or breastfeeding/nursing women.
  • Abnormal fasting blood comprehensive metabolic panel, complete blood count, C-reactive protein, and urinalysis. Inaccurate 24-hour urine collections.
  • Healthy subjects: Currently taking or have recently taken medications within the last 3 months (i.e. antibiotics) or dietary supplements. History of KS or any medical condition that could influence absorption or excretion of oxalate.
  • Active illness including COVID-19, flu, common cold, fever, diarrhea, urinary tract infections, or other infections 14 days before the study and throughout the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (estimated)

Study arms

  • Experimental
    Healthy Participants

    Healthy participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day "washout" period on a self-selected diet, and finally the opposite diet from the first for the last four days.

    Dietary Supplement: Low Oxalate Diet · Dietary Supplement: High Oxalate Diet

  • Experimental
    Calcium Oxalate Kidney Stone

    Calcium oxalate kidney stone participants will randomly receive either high (250mg) or low (40mg) oxalate diet for for four days, a ten day "washout" period on a self-selected diet, and finally the opposite diet from the first for the last four days.

    Dietary Supplement: Low Oxalate Diet · Dietary Supplement: High Oxalate Diet

Interventions

  • Dietary supplementLow Oxalate Diet

    Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

  • Dietary supplementHigh Oxalate Diet

    Participants will consume a diet that is controlled in its daily contents of oxalate and calcium, and in its content of carbohydrate, fat, and protein. Participants will be asked not to take any dietary supplements, exercise strenuously, or consume food or drink that is not provided to them.

06

What researchers measure

Primary outcomes

  1. Change in Urinary Oxalate

    Twenty-four hour urinary oxalate will be reported as mg/day.

    Time frame: Days 3-4 and 13-14

  2. Change in Nanocystalluria

    Nanocrystalluria will be reported as particles/ml.

    Time frame: Days 3-4 and 13-14

  3. Monocyte Cellular Bioenergetics and Mitochondrial Function

    Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells).

    Time frame: Day 1

  4. Monocyte Cellular Bioenergetics and Mitochondrial Function

    Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells).

    Time frame: Day 4

  5. Monocyte Cellular Bioenergetics and Mitochondrial Function

    Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells).

    Time frame: Day 11

  6. Monocyte Cellular Bioenergetics and Mitochondrial Function

    Cellular bioenergetics and mitochondrial function will be reported as oxygen consumption rate (pmol/min/10,000 cells).

    Time frame: Day 14

  7. Monocyte Subtypes

    Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity).

    Time frame: Day 1

  8. Monocyte Subtypes

    Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity).

    Time frame: Day 4

  9. Monocyte Subtypes

    Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity).

    Time frame: Day 11

  10. Monocyte Subtypes

    Monocyte subtypes will be determined using flow cytometry (mean fluorescence intensity).

    Time frame: Day 14

  11. Monocyte Transcriptomics

    Monocyte transcriptomics will be reported as gene expression (mRNA levels)

    Time frame: Day 1

  12. Monocyte Transcriptomics

    Monocyte transcriptomics will be reported as gene expression (mRNA levels)

    Time frame: Day 4

  13. Monocyte Transcriptomics

    Monocyte transcriptomics will be reported as gene expression (mRNA levels)

    Time frame: Day 11

  14. Monocyte Transcriptomics

    Monocyte transcriptomics will be reported as gene expression (mRNA levels)

    Time frame: Day 14

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2023 (actual). Primary completion is estimated for May 2027, 48 months after the start.

Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 48 months is above that.

Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2022
First posted
Jun 14, 2022
StartActual
May 19, 2023
Primary completionEst.
May 30, 2027
CompletionEst.
May 30, 2027
Last update
May 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05417568
Responsible party
Tanecia Mitchell, PhD (Principal Investigator, University of Alabama at Birmingham) — Principal investigator
First posted
Jun 14, 2022
Start date
May 19, 2023
Primary completion
May 30, 2027 (estimated)
Completion
May 30, 2027 (estimated)
Last update
May 15, 2026

Study contacts

Tanecia Mitchell, PhD
Contact
taneciamitchell@uabmc.edu
(205) 996-2292
Tanecia Mitchell, PhD
principal investigator · University of Alabama at Birmingham

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion